The rat arcuate nucleus integrates peripheral signals provided by leptin, insulin, and a ghrelin mimetic.

Hewson AK, Tung LY, Connell DW, Tookman L, Dickson SL

Diabetes1 Dec 2002Cited by 90 (Europe PMC)

PMID12453894DOI10.2337/diabetes.51.12.3412PepBankPUB-12453894

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

01AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism
In fasted rats, central insulin suppressed the increased Fos response to GHRP‑6.
In plain wordsIn rats, central insulin reduced the increased response to GHRP‑6 during fasting.
Peptide
GHRP-6
Outcome
DecreaseFos response with central insulin
Study
ratn: not reported in source
fasted rats
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Source sentences
Summary
Chronic central infusion of insulin or leptin during a 48-h fast suppressed the threefold increase in the Fos response to intravenous injection of a maximally effective dose of growth hormone-releasing peptide (GHRP)-6, a synthetic growth hormone secretagogue.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1245389401
02AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism
In fasted rats, central leptin suppressed the increased Fos response to GHRP‑6.
In plain wordsIn rats, central leptin reduced the increased response to GHRP‑6 during fasting.
Peptide
GHRP-6
Outcome
DecreaseFos response with central leptin
Study
ratn: not reported in source
fasted rats
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Source sentences
Summary
Chronic central infusion of insulin or leptin during a 48-h fast suppressed the threefold increase in the Fos response to intravenous injection of a maximally effective dose of growth hormone-releasing peptide (GHRP)-6, a synthetic growth hormone secretagogue.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1245389402
03AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism
In obese Zucker rats, the GHRP‑6-induced Fos response was twofold greater than in lean controls.
In plain wordsIn obese Zucker rats, GHRP‑6 produced a greater Fos response than in lean controls.
Peptide
GHRP-6
Outcome
IncreaseFos response in obese Zucker rats
Study
ratn: not reported in source
obese Zucker rats
Comparator
lean controls
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Source sentences
Summary
Furthermore, the GHRP-6-induced Fos response was twofold greater in obese leptin- and insulin-resistant Zucker rats compared with lean controls.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1245389403

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.